Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

IBUPROFEN ANALGESICS CONTINUE TO GAIN MARKETSHARE primarily at the expense of aspirin and aspirin-containing analgesic compounds, according to recent audit data from Information Resources, Inc. subsidiary Towne-Oller & Associates. Retail sales of ibuprofen- based OTC analgesics in food and drug stores grew 11% in the 12- month period from May 1992 through April 1993 to $ 564 mil. Ibuprofen-containing products increased their share of the nearly $ 2.4 bil. OTC analgesic market by more than one-and-a-half share points to 23.8% during the 12-month period through April 1993, the Towne-Oller data show (see chart below). Each share point in the OTC analgesic market is currently worth about $ 24 mil. in sales. Acetaminophen analgesics, led by McNeil's Tylenol line, still dominate the market with a 47% share as retail sales continue to grow faster than the overall market. For the 12 months through April 1993, acetaminophen analgesic product sales at retail increased 5% to over $ 1.1 bil. The overall analgesic market grew 3.6% to $ 2.37 mil. for the 12 months through April. Sales of aspirin-based analgesic compounds fell 5% to $ 400.9 mil. with the group's marketshare slipping to 16.4%. Aspirin product sales declined 3% to $ 289.6 mil. and marketshare fell to 12.2%. Chart omitted.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts